We’re pleased to share that Biocytogen will attend Summit4CI in Vancouver, Canada between March 29th - 31st, 2026. This special event is dedicated to increasing patient scholar-researcher collaboration, with the goal of gaining a better understanding of cancer biology and immunotherapy. Let’s connect and share insights to drive new developments in the field!
What is Summit 4CI?
The Summit for Cancer Immunotherapy (Summit4CI) is the annual major gathering of BioCanRx, Canada’s Immunotherapy Network. Bringing together 350 industry leaders, students, and policy makers, the conference highlights the latest breakthroughs from scientific, industry, and patient perspectives. Meaningful conversations and collaborations will be fostered through expert-led sessions, debates, and networking opportunities.
Event Overview
Date: March 29th - 31st, 2026.
Venue: The Westin Bayshore, 1601 Bayshore Dr., Vancouver, BC V6G 2V4, Canada
Event Schedule
For more information, please refer to the conference program.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to meeting you in Vancouver!
